SVision Imaging Rebrands as Intalight, Names Joe Garibaldi as COO

By Staff
Friday, November 18, 2022 12:27 AM MILPITAS, Calif.—SVision Imaging, a company that develops advanced ophthalmic technologies such as optical coherence tomography (OCT), is rebranding under the new name Intalight.

EyeSouth Partners Affiliates With University Retina and Macula Associates, Representing the Network’s 34th Affiliation and Third in Illinois

By Staff
Wednesday, November 16, 2022 12:27 AM ATLANTA—EyeSouth Partners announced it has completed an affiliation with University Retina and Macula Associates. The affiliation represents EyeSouth’s third in the state of Illinois and 34th affiliation overall.

Many Parents Don’t Seek Medical Help When Their Child Get Pink Eye, New Study Reveals

By Staff
Tuesday, November 15, 2022 1:55 PM As most eyecare professionals know, pink eye, an inflammation of the transparent membrane in the eye, is one of the most common eye conditions that children can develop. It is most common in children under the age of seven.

30 percent of parents say they don’t go to the doctor or urgent care if they think their child has pink eye, according to a new study by MyVision.org.

Sight360 Acquires Florida Ophthalmology Practice

By Staff
Thursday, November 10, 2022 12:24 AM TAMPA, Fla.—Sight360, a comprehensive vision care services organization, announced it has acquired the ophthalmology practice of Larry Goldberg, MD, in St. Petersburg, Fla. The terms of the transaction were not disclosed.

Vision Integrated Partners Expands in Greater Kansas City Market

By Staff
Wednesday, November 9, 2022 12:24 AM NEW YORK—Vision Integrated Partners, a managed services organization backed by Firmament that provides non-medical services to its network of eyecare professionals, announced 2 new partnerships.

Ocuphire Pharma, FamyGen Life Sciences Sign $35 Million Global License Agreement for Nyxol Eye Drops

By Staff
Wednesday, November 9, 2022 12:15 AM FARMINGTON HILLS, Mich.—Ocuphire Pharma has concluded an exclusive license agreement with FamyGen Life Sciences (Famy) for the development and commercialization of Nyxol across three indications in the U.S., Europe, Japan, India, China and other global markets. In connection with its separately announced transaction with Famy, Viatris, a leading global health care company, has agreed to commercialize Nyxol following each regulatory approval. “Famy and Ocuphire have been engaging for several months, in a collaborative spirit, to conclude this agreement.

Oyster Point Pharma to Be Acquired by Viatris

By Staff
Tuesday, November 8, 2022 12:24 AM PRINCETON, N.J.—Oyster Point Pharma (Nasdaq: OYST), a leading ophthalmology-focused biopharmaceutical company, yesterday announced that it has entered into a definitive agreement under which it would be acquired by Viatris Inc. (Nasdaq: VTRS), a global health care company. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmology franchise, recognizing its management team, the strength of Tyrvaya (varenicline solution) Nasal Spray and Oyster Point Pharma’s pipeline, according to a statement released by Oyster Point Pharma.

Unifeye Vision Partners Completes Newest Partnership With Eye Care of San Diego

By Staff
Monday, November 7, 2022 12:27 AM DALLAS—Unifeye Vision Partners, a leading network of comprehensive eyecare providers, announced the completion of a strategic partnership with Eye Care of San Diego, based in Mission Hills, Calif.

Vyluma Reports Positive Results from Clinical Trial for Childhood Atropine for Myopia Progression

By Staff
Thursday, November 3, 2022 12:18 AM BRIDGEWATER, N.J.—Vyluma, Inc., a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced positive top-line results from its Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of the multi-center, international study, performed after three years of treatment and follow-up, demonstrates strong safety and efficacy for NVK002, a low dose, preservative-free atropine eye drop, as a potential treatment for the progression of myopia in children, according to Vyluma which shared the results last week at the American Academy of Optometry annual meeting in San Diego, Calif.

BioTissue Holdings Completes Name Change

By Staff
Thursday, November 3, 2022 12:15 AM MIAMI—BioTissue Holdings Inc. has completed its name change from TissueTech, Inc. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Following the name change, the former TissueTech, Inc. has become BioTissue Holdings Inc., and its subsidiaries BioTissue Inc. is now BioTissue Ocular Inc., and the former Amniox Medical, Inc. is now BioTissue Surgical Inc. The biotech company, based here, harnesses human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound and musculoskeletal applications.

Tracking the Frequency of Eye Doctor Visits

By Staff
Tuesday, November 1, 2022 2:11 PM NVision, a leading provider of ophthalmic physician services, surveyed more than 1,000 people across the U.S. to find out how often they visit an eye doctor. Forty-eight percent of respondents go at least once a year, 21 percent every two years, 18 percent visit every three to five years, 10 percent go every six to ten years or longer, and 3 percent have never been to the eye doctor at all.

Aurion Biotech Wins Prix Galien Award

By Staff
Tuesday, November 1, 2022 12:15 AM SEATTLE, BOSTON and TOKYO—Aurion Biotech, a clinical-stage biotech company that develops regenerative therapies, has won the prestigious Prix Galien Award for Best Startup in Biotech/Pharma. The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. “The Prix Galien is known throughout the world for its ability to shine a bright light on the most important, impactful innovations in medicine, biotechnology, health care and the life sciences,” said Greg Kunst, Aurion Biotech chief executive officer.

Lumata Health Raises $4 Million in Series A Funding to Scale Eyecare Management Platform

By Staff
Monday, October 31, 2022 12:18 AM RALEIGH, N.C. and OKLAHOMA CITY. Okla.—Lumata Health, a health care startup based in Oklahoma City, announced $4 million in new venture funding to scale its impact throughout the U.S. The funding round was led by Cortado Ventures, joined with participation by the Wolfpack Investor Network and 30 practicing ophthalmologists across the U.S. Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and health systems, according to an announcement.

Eyenuk Secures $26 Million Series A Funding to Accelerate Global Access to AI-Powered Eye-Screening Technology

By Staff
Thursday, October 20, 2022 12:21 AM LOS ANGELES—Eyenuk, a global artificial intelligence (AI) digital health company, announced it has secured $26 million in a Series A financing round, bringing the company’s total funding to over $43 million.

Nicox 3Q 2022 Revenue Dips Below €1 Million

By Staff
Thursday, October 20, 2022 12:18 AM SOPHIA ANTIPOLIS, France—Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported net revenue of €0.8 million for third quarter ending Sept. 30, 2022.